Blood-based biomarkers in Alzheimer's disease: Future directions for implementation.

ABSTRACT:

Introduction

Disease-modifying therapies (DMTs) for Alzheimer's disease (AD) will increase diagnostic demand. A non-invasive blood-based biomarker (BBBM) test for detection of amyloid-β pathology may reduce diagnostic barriers and facilitate DMT initiation.

Objective

To explore heterogeneity in AD care pathways and potential role of BBBM tests.

Methods

Survey of 213 healthcare professionals/payers in US/China/UK/Germany/Spain/France and two advisory boards (US/Europe).

Results

Current diagnostic pathways are heterogeneous, meaning many AD patients are missed while low-risk patients undergo unnecessary procedures. Confirmatory amyloid testing (cerebrospinal fluid biomarkers/positron emission tomography) is utilized in few patients, resulting in diagnostic/treatm

SUBMITTER: Suridjan I 

PROVIDER: S-EPMC10696162 | biostudies-literature | 2023 Oct-Dec

REPOSITORIES: biostudies-literature